Welcome to our dedicated page for Viatris news (Ticker: VTRS), a resource for investors and traders seeking the latest updates and insights on Viatris stock.
Viatris Inc. (NASDAQ: VTRS) is a global healthcare company that bridges the gap between generics and branded medicines, aiming to address healthcare needs more comprehensively worldwide. Formed in November 2020 by the merger of Upjohn, a subsidiary of Pfizer, and Mylan, Viatris leverages its vast portfolio to provide high-quality medications to approximately 1 billion patients annually across more than 165 countries. The company’s operations span 10 major therapeutic areas, with a strategic focus on dermatology, ophthalmology, and gastroenterology.
Viatris boasts an extensive product lineup, including around 1,400 generic pharmaceuticals and several branded medications like Lipitor, Norvasc, Lyrica, and Viagra. Generics and biosimilars form about 40% of its sales, while legacy products contribute to the remaining 60%. The company is also a key supplier of antiretroviral therapies, which nearly 50% of HIV/AIDS patients in developing countries rely on.
In 2023, Viatris continued to make strides with significant developments. It announced positive results from the YUPELRI® Phase III clinical trial in China for COPD treatment, paving the way for regulatory approval anticipated in mid-2024. The company also entered a substantial R&D collaboration with Idorsia Ltd, acquiring global rights to two promising Phase 3 assets: selatogrel, for acute myocardial infarction, and cenerimod, for systemic lupus erythematosus. Additionally, Viatris launched RYZUMVI™, an FDA-approved eye drop for reversing pharmacologically-induced dilation, further expanding its ophthalmology portfolio.
Financially, Viatris demonstrated robust performance with consistent operational revenue growth. The company reported a strong 2023, meeting its financial guidance, and executed strategic initiatives like the divestiture of its Women's Healthcare Business and API business in India. Viatris also maintained a solid cash flow, allowing it to return capital to shareholders through dividends and share repurchases, reinforcing its commitment to shareholder value.
Headquartered in the U.S., with major centers in Pittsburgh, Shanghai, and Hyderabad, Viatris employs around 30,000 people dedicated to advancing global health. For more information, visit viatris.com.
Viatris Inc. (NASDAQ: VTRS) will host an investor event on February 28, 2022, at 8:30 a.m. ET, where the CEO, President, and CFO will present the company's fourth quarter and full year 2021 financial results. The event will provide insights into Viatris' two-phased strategic roadmap. Interested investors can access a live webcast at investor.viatris.com, with an archived version available afterward. Viatris focuses on delivering high-quality medicines globally, with over 1,400 approved molecules across various therapeutic areas.
Viatris Inc. (NASDAQ: VTRS) announced FDA approval for Cyclosporine Ophthalmic Emulsion 0.05%, the first generic version of Allergan's Restasis®, allowing immediate market launch. With no remaining regulatory barriers, Viatris aims to enhance access to affordable treatments for chronic dry eye disease. This approval represents a significant milestone for Viatris, highlighting its commitment to innovation and patient access.
Viatris Inc. (NASDAQ: VTRS) announced a 9% increase in its quarterly dividend, now set at 12 cents ($0.12) per share, payable on March 16, 2022. This marks the fourth consecutive quarterly dividend declaration, positioning the annual dividend rate for 2022 at 48 cents ($0.48) per share. CEO Michael Goettler expressed satisfaction with the company's operational momentum and commitment to returning capital to shareholders. The record date for this dividend is February 24, 2022.
Viatris Inc. (NASDAQ: VTRS) announced that the U.S. Patent and Trademark Appeal Board affirmed its previous rulings declaring several of Sanofi's Lantus® SoloSTAR® device patents unpatentable. This decision is a significant win for Viatris, facilitating wider access to its interchangeable Semglee® products, which are now the only interchangeable biosimilars for Lantus®. These products aim to provide affordable insulin options for diabetes patients, allowing substitution at pharmacies. Viatris' commitment to enhancing patient access is evident through its Global Healthcare Gateway® initiative.
Viatris Inc. (NASDAQ: VTRS) has announced a rescheduling of its investor event from January 7, 2022, to a date no later than February 28, 2022, coinciding with the release of its fourth quarter 2021 results. The company reaffirmed its 2021 financial guidance originally provided on November 8, 2021. During the event, Viatris will present details on its two-phased strategic roadmap, covering financial guidance and metrics for Phase I (2022-2023) and growth catalysts for Phase II (2024 and beyond), including capital allocation priorities and pipeline developments.
On December 1, 2021, Viatris (NASDAQ: VTRS) announced that the U.S. Court of Appeals affirmed a prior ruling that invalidated Biogen's Tecfidera patent for lack of written description. This decision supports Viatris' launch of a generic version of Tecfidera in August 2020, facilitating greater access to multiple sclerosis treatments. CEO Michael Goettler expressed satisfaction with the ruling, highlighting Viatris' commitment to improving patient access to affordable medications.
Viatris Inc. (NASDAQ: VTRS) will participate in a virtual fireside chat at the Evercore ISI 4th Annual HealthCONx Conference on December 1, 2021, at 7:30 a.m. ET. Executives Michael Goettler, Rajiv Malik, and Sanjeev Narula will engage in a discussion regarding company insights. Investors can access the live webcast at investor.viatris.com. An archived version will also be available post-event. Viatris aims to empower global healthcare access and provides over 1,400 approved molecules in diverse therapeutic areas.
Viatris (NASDAQ: VTRS) and Biocon Biologics announced the U.S. launch of interchangeable biosimilars SEMGLEE® (insulin glargine-yfgn) and Insulin Glargine (insulin glargine-yfgn) to aid in controlling high blood sugar for diabetes patients. Both products are available in various forms and can be substituted for the reference brand LANTUS®. Viatris emphasizes their commitment to improving access to affordable healthcare through a range of patient assistance programs, including copay and cash-pay options, effective from 2022.
Viatris Inc. (NASDAQ: VTRS) announced a $1 million donation to SBP, focusing on the Got Your Back Fund, which supports low-to-moderate income U.S. veterans in disaster recovery. This partnership aims to address housing instability exacerbated by COVID-19 by providing rebuilt and modified homes for veterans with disabilities. Viatris has contributed over $3 million to SBP since 2016, reinforcing its commitment to social support. The CEO emphasized the importance of funding in disaster recovery, particularly for veterans, while SBP's CEO expressed gratitude for Viatris's support in easing access to assistance.
FAQ
What is the current stock price of Viatris (VTRS)?
What is the market cap of Viatris (VTRS)?
What is Viatris Inc.?
What products does Viatris offer?
What are Viatris' key therapeutic areas?
What recent collaborations has Viatris announced?
How did Viatris perform financially in 2023?
Where is Viatris headquartered?
What is YUPELRI®?
What is the significance of RYZUMVI™?
What is the mission of Viatris?
How many people does Viatris employ?
